Market Place
Sourcing Support
InMed`s INM-901 Shows Promise As Multi-Factorial Approach For Alzheimer`s
23 Jul 2024 //
FIERCE BIOTECH
InMed Reports Q2 Fiscal 2023 Financial Results and Provides Business Update
17 Feb 2023 //
GLOBENEWSWIRE
InMed Submits Form 12b-25
09 Feb 2023 //
GLOBENEWSWIRE
InMed Provides Business Update and Milestones for 2023
10 Jan 2023 //
GLOBENEWSWIRE
InMed Announces Results of 2022 Annual General Meeting
15 Dec 2022 //
GLOBENEWSWIRE
InMed Announces Appointment Interim Chief Financial Officer & Change of Auditor
12 Dec 2022 //
GLOBENEWSWIRE
InMed Announces Closing of $6 M Private Placement Priced at a Premium to Market
21 Nov 2022 //
GLOBENEWSWIRE
InMed Pharma Announces $6 M Private Placement Priced at Market
18 Nov 2022 //
GLOBENEWSWIRE
InMed Provides Update on Management Changes
17 Nov 2022 //
BIOSPACE
InMed Advances Neurodegenerative Disease Program with ("NSERC")
16 Nov 2022 //
GLOBENEWSWIRE
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results
11 Nov 2022 //
GLOBENEWSWIRE
InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week
26 Oct 2022 //
GLOBENEWSWIRE
InMed Pharmaceuticals Shares Rise 30% on Higher-Than-Normal Volume
30 Sep 2022 //
MARKETWATCH
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results
23 Sep 2022 //
GLOBENEWSWIRE
Cancer biotech Elicio Therapeutics withdraws $40 million IPO
13 Sep 2022 //
RENAISSANCECAPITAL
InMed Announces Closing of $6 Million Private Placement Priced
13 Sep 2022 //
GLOBENEWSWIRE
InMed Announces $6 Million Private Placement Priced at a Premium to Market
09 Sep 2022 //
GLOBENEWSWIRE
Cannabinoid-focused drugmaker InMed backs away from H&W sector
09 Sep 2022 //
FIERCEBIOTECH
InMed Pharmaceuticals Provides Update on its Core Research and Development
08 Sep 2022 //
GLOBENEWSWIRE
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria
23 Aug 2022 //
GLOBENEWSWIRE
InMed Announces Changes to its Board of Directors
09 Aug 2022 //
GLOBENEWSWIRE
InMed Announces Update on PII Trial Investigating INM-755 Cannabinol Cream
25 Jul 2022 //
GLOBENEWSWIRE
InMed Announces Appointment of Chief Operating Officer
18 Jul 2022 //
GLOBENEWSWIRE
InMed Pharma Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
12 Jul 2022 //
GLOBENEWSWIRE
InMed Publishes Peer-Reviewed Study Shows Potential Role of Rare Cannabinoids
14 Jun 2022 //
GLOBENEWSWIRE
InMed Launches THCV
09 Jun 2022 //
GLOBENEWSWIRE
InMed Pharma Closes $5M Registered Direct and Private Placement Offerings
06 Jun 2022 //
GLOBENEWSWIRE
InMed Pharma Announces $5M Registered Direct and Private Placement Offerings
02 Jun 2022 //
GLOBENEWSWIRE
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results
13 May 2022 //
GLOBENEWSWIRE
InMed to Supply Rare Cannabinoids to Radicle Science`s Radicle Energy Study
05 May 2022 //
GLOBENEWSWIRE
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and more
28 Apr 2022 //
GLOBENEWSWIRE
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid
21 Apr 2022 //
GLOBENEWSWIRE
InMed to Participate in Upcoming Investor Conferences in April and May 2022
19 Apr 2022 //
GLOBENEWSWIRE
InMed says Management Changes
17 Mar 2022 //
GLOBENEWSWIRE
InMed to Present at the 34th Annual Roth Conference
08 Mar 2022 //
GLOBENEWSWIRE
InMed Reports Q2 Fiscal 2022 Financial Results, Provides Business Update
14 Feb 2022 //
GLOBENEWSWIRE
InMed Pharma to Report Q2 Fiscal 2022 Financial Results and Business Update
10 Feb 2022 //
GLOBENEWSWIRE
InMed Launches CBT Expanding its Rare Cannabinoid Portfolio
19 Jan 2022 //
GLOBENEWSWIRE
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article
20 Dec 2021 //
GLOBENEWSWIRE
InMed Files PCT Patent Application for Treating Neurodegenerative Disease
03 Nov 2021 //
GLOBENEWSWIRE
InMed shares jump 8% after completing BayMedica deal
13 Oct 2021 //
SEEKINGALPHA
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results
24 Sep 2021 //
GLOBENEWSWIRE
InMed and BayMedica Participating in Tribe Public’s Webinar
17 Sep 2021 //
GLOBENEWSWIRE
InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results
17 Sep 2021 //
GLOBENEWSWIRE
InMed Announces Closing of US$12M Private Placement
02 Jul 2021 //
GLOBENEWSWIRE
InMed Signs Non-binding Letter of Intent to Acquire BayMedica
29 Jun 2021 //
GLOBENEWSWIRE
InMed Announces $12M Private Placement Priced At-the-Market under Nasdaq Rules
29 Jun 2021 //
GLOBENEWSWIRE
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica
29 Jun 2021 //
BIOSPACE
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica
28 Jun 2021 //
BIO SPACE
InMed Pharmaceuticals to Webcast Live at Life Sciences Investor Forum June 24th
22 Jun 2021 //
GLOBENEWSWIRE
InMed Pharma Increases Cannabinoid Yield to 5 g/L with IntegraSyn
17 Jun 2021 //
GLOBENEWSWIRE
InMed Pharma submits CTA to evaluate INM-755 cream in phase 2 trial
29 Apr 2021 //
PHARMABIZ
InMed Announces Closing of US$4.5 Million Private Placement
16 Feb 2021 //
PRNEWSWIRE
InMed to Participate in 2021 Cannabinoid-Derived Pharmaceuticals
19 Jan 2021 //
PRNEWSWIRE
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755
08 Jan 2021 //
PRNEWSWIRE
InMed Licenses MiDROPS® Delivery Technology from EyeCRO
03 Dec 2020 //
PRNEWSWIRE
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN
25 Nov 2020 //
PRNEWSWIRE
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream
25 Nov 2020 //
PRNEWSWIRE
InMed and BayMedica Announce Collaboration for Manufacturing
18 Nov 2020 //
PRNEWSWIRE
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering
16 Nov 2020 //
PRNEWSWIRE
